P
Pear Therapeutics
Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need
At a glance
- Founded
- 2013
- Headquarters
- Boston, United States
- Listing
- Public via SPAC 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Pear Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- JPJAZZ Venture Partners
- BCBridge Builders Collaborative
- AVArboretum Ventures
- NONovartis
- 5V5AM Ventures
Series B and later12 investors entered at this stage
- UVUniversity of Virginia
Temasek- SGShanda Group
- QMQUAD Investment Management
- PVPilot House Ventures
- EDEDBI
- DCDartmouth College
- KIKarolinska Institute
SoftBank
SoftBank Vision Fund- TPTrustbridge Partners
- UCUniversity of Southern California
Source: Dealroom Talent Intelligence.
Alumni founders
Former Pear Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
Eric LeuthartUnited States
ATAffini-T TherapeuticsEst. 2020
Arjun GoyalUnited States
NBNew Frontier BioEst. 2020
Kirthiga ReddyUnited StatesGlobal footprint
across markets
Patents
8 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pear Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pear Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

